Gautam Chukka
Stock Analyst at Chardan Capital
(0.71)
# 4,224
Out of 5,133 analysts
7
Total ratings
60%
Success rate
-15.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gautam Chukka
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Initiated Coverage: Buy | $8 | $1.16 | +592.64% | 1 | Oct 20, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterated: Buy | $25 | $12.12 | +106.36% | 1 | Oct 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $240 | $153.18 | +56.68% | 1 | Sep 21, 2026 | |
| ADAG Adagene | Initiated Coverage: Buy | $9 | $2.00 | +350.00% | 1 | Sep 10, 2026 | |
| TENX Tenax Therapeutics | Downgraded: Hold | $27 → $5 | $1.61 | +210.56% | 3 | Aug 11, 2026 |
Tvardi Therapeutics
Oct 20, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.16
Upside: +592.64%
4D Molecular Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: $25
Current: $12.12
Upside: +106.36%
Palvella Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $240
Current: $153.18
Upside: +56.68%
Adagene
Sep 10, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $2.00
Upside: +350.00%
Tenax Therapeutics
Aug 11, 2026
Downgraded: Hold
Price Target: $27 → $5
Current: $1.61
Upside: +210.56%